Ruiyang Yan

Dr. Ruiyang Yan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
JHJoseph Edward Haigh
Joseph Edward Haigh
SRSamuel Rack
Samuel Rack
RYRuiyang Yan
Ruiyang Yan
SBSherin Babu
Sherin Babu
ODOlly Donnelly
Olly Donnelly
RMRobert Metcalf
Robert Metcalf
Cutaneous squamous cell carcinoma (cSCC) is a common cancer with increasing incidence and 5% of patients develop incurable disease, often resistant to chemotherapy. The anti-PD-1 therapy cemiplimab has shown high efficacy in clinical trials. This retrospective study evaluated the real-world effectiveness of cemiplimab in incurable cSCC and examined factors influencing response and toxicity. Data from 86 patients across three UK healthcare providers were analysed. Median progression-free survival (PFS) and overall survival (OS) were not reached, with 38% showing durable responses beyond 12 months. The overall response rate was 60.8% (95% CI 49–71), and the clinical benefit rate was 74.3% (95% CI 63–83). A head and neck primary site was associated with improved PFS (p = 0.008) and OS (p = 0.023), while concurrent immunosuppression was associated with worse PFS (p < 0.001). These findings align with clinical trials, suggesting cemiplimab is effective and safe in the recurrent/metastatic setting.

4 March 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JHJoseph Edward Haigh
Joseph Edward Haigh
SRSamuel Rack
Samuel Rack
RYRuiyang Yan
Ruiyang Yan
SBSherin Babu
Sherin Babu
ODOlly Donnelly
Olly Donnelly
RMRobert Metcalf
Robert Metcalf
Cutaneous squamous cell carcinoma (cSCC) is a common cancer with increasing incidence and 5% of patients develop incurable disease, often resistant to chemotherapy. The anti-PD-1 therapy cemiplimab has shown high efficacy in clinical trials. This retrospective study evaluated the real-world effectiveness of cemiplimab in incurable cSCC and examined factors influencing response and toxicity. Data from 86 patients across three UK healthcare providers were analysed. Median progression-free survival (PFS) and overall survival (OS) were not reached, with 38% showing durable responses beyond 12 months. The overall response rate was 60.8% (95% CI 49-71), and the clinical benefit rate was 74.3% (95% CI 63-83). A head and neck primary site was associated with improved PFS (p=0.008) and OS (p=0.023), while concurrent immunosuppression was associated with worse PFS (p<0.001). These findings align with clinical trials, suggesting cemiplimab is effective and safe in the recurrent/metastatic setting.